Author: Hanh Nguyen
-
7th Annual Methods Summit — Summary Report
The 7th Annual Methods Summit was held on March 25, 2026 at the USC Capital Campus in Washington, D.C. The event convened leaders in value research, policy, and patient advocacy to examine how value assessment can better reflect the full spectrum of what matters to patients. Grounded in IVI’s principles of methodological rigor, transparency, equity,…
-
New Video: Rare Disease Patient Engagement Checklist
IVI has released a new video introducing the Rare Disease Patient Engagement (RDPE) Checklist, a practical framework designed to help researchers embed patient and caregiver perspectives across all phases of rare disease value research and assessment. The video highlights why meaningful engagement matters, how lived experience strengthens evidence generation, and practical steps research teams can…
-
IVI at ISPOR 2026
IVI will participate in ISPOR 2026 through poster presentations and invited panel discussions focused on patient-centered value assessment, outcomes research, methodological innovation, and healthcare decision-making. Throughout the conference, IVI researchers and collaborators will share work spanning rare disease patient engagement, mental health outcomes research, machine learning applications, and broader discussions on equity and patient-reported outcomes.…
-
New in AJMC: Prioritizing Patient-Centered Value Over International Reference Pricing in U.S. Drug Policy
IVI is pleased to share a new commentary published in the AJMC® Contributor Column: “Prioritizing Patient-Centered Value Over International Reference Pricing in U.S. Drug Policy,” by Dominique Seo, MPH; Panos Kanavos, PhD; Eleanor M. Perfetto, PhD, MS; and Tiffany Huth, MPH. As policymakers consider international reference pricing (IRP) and most-favored nation (MFN) models as tools…
-
PRESS RELEASE: From Principle to Practice: New Checklist Supports Patient Engagement in Rare Disease Value Research
IVI, a non-profit research organization committed to advancing the science, practice, and use of health technology assessment (HTA) in healthcare, is proud to announce the launch of the Rare Disease Patient Engagement (RDPE) Guidance and Checklist, a practical, downloadable resource designed to support meaningful patient and caregiver engagement across all phases of rare disease research…
-
PRESS RELEASE: IVI Appoints Marc Boutin as President & Chief Executive Officer
IVI today announced the appointment of Marc Boutin as its new President and Chief Executive Officer, effective February 18, 2026. A family caregiver, patient advocate, executive, and patient himself, Boutin brings a lived perspective that informs his leadership at the Center. He also brings more than two decades of experience advancing patient-centered health policy, building…
-
IVI Announces the Appointment of Five New Board Members
IVI (IVI), a non-profit research organization committed to advancing the science, practice, and use of value assessment in healthcare announced the addition of five new members to its 2026 Board of Directors: Elizabeth Cope, PhD, MPH (Chief Programs & Science Officer, AcademyHealth), Amy Duhig, PHD (Senior Director, New Product Planning, Value and Evidence Generation, Takeda…
-
IVI Calls for Stronger Patient Partnership and Real Consideration of Novel Value Elements in HEMA’s Draft Methods Report
In its public comments on the Health Economics Methods Advisory (HEMA) group’s draft report, “Defining Appropriate Benefits for Economic Evaluation of Health Care Technologies,” the IVI urged HEMA to strengthen its framework for defining benefits in economic evaluation. IVI called for patients and caregivers to be engaged as co-creators in methods development, for equity to…
-
Q&A with Center Health Equity Fellow
As her Health Equity Fellowship comes to a close, we’re proud to spotlight Dominique Seo, PhD candidate in Pharmaceutical Health Services Research at the University of Maryland, Baltimore. Over the past year, Dominique has brought deep expertise in pharmacoeconomics, with a focus on drug pricing, access, and health disparities, to the IVI. We sat down…
-
Center Statement re: Trump’s Ultimatum on MFN
IVI shares the public’s urgency in addressing the affordability of prescription drugs and healthcare in the United States. However, as momentum builds around aggressive policy proposals like the Most Favored Nation (MFN) pricing model, we urge policymakers to pause and ask a critical question: What do these policies mean for patients? As we have emphasized in…